Sugi Predict

Sugi Predict / Compounds / SCHEMBL2420439

SCHEMBL2420439

SCHEMBL2420439

CC(C)(C)OC(=O)N1CCN(C(=O)OCc2ccccc2)CC1CO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.63
▸ PDK1 Q15118 1/20 0.51
▸ PDK2 Q15119 1/20 0.51
▸ PDK3 Q15120 1/20 0.51
▸ PDK4 Q16654 1/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ OPRK1 P41145 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ NR1H2 P55055 2/20 0.46
▸ NR1H3 Q13133 2/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ ABHD6 Q9BV23 1/20 0.44
▸ DAGLA Q9Y4D2 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ JAK1 P23458 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129602 1.00 PARP1 (0.63) PARP1PDK1PDK2PDK3PDK4
SCHEMBL6334954 1.00 PARP1 (0.63) PARP1PDK1PDK2PDK3PDK4
SCHEMBL778980 0.96 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL17068124 0.96 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL4828910 0.96 PARP1 (0.58) PARP1PDK1PDK2PDK3PDK4
SCHEMBL8230203 0.91 PARP1 (0.61) PARP1PDK1PDK2PDK3PDK4
SCHEMBL12172480 0.91 PARP1 (0.61) PARP1PDK1PDK2PDK3PDK4
SCHEMBL16680548 0.91 PARP1 (0.61) PARP1PDK1PDK2PDK3PDK4
SCHEMBL30440068 0.91 PARP1 (0.63) PARP1PDK1PDK2PDK3PDK4
SCHEMBL8116641 0.91 PARP1 (0.63) PARP1PDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739670-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-13 — — EP disclosed
WO-2025264844-A1 HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF LIEBER INSTITUTE, INC. (US) 2025-12-26 — — WO disclosed
US-12319679-B2 Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2025-06-03 — — US disclosed
US-12286434-B2 Pan-tropic entry inhibitors EMORY UNIVERSITY (US) 2025-04-29 — — US disclosed
WO-2025012057-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2025-01-16 — — WO disclosed
CN-118574834-A Fused tetracyclic compounds, compositions and uses thereof 泰博生物科技股份有限公司 2024-08-30 — — CN disclosed
CN-118005655-A Condensed ring compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-05-10 — — CN disclosed
CN-112384509-B Furin inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2024-04-30 — — CN disclosed
CN-117886881-A Chimeric compound for targeted degradation of BCL-2 protein, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-04-16 — — CN disclosed
EP-4327814-A2 MORPHOLINYL, PIPERAZINYL, OXAZEPANYL AND DIAZEPANYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS Biogen MA Inc. (US) 2024-02-28 — — EP disclosed
US-20130338142-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2013-12-19 — — US disclosed
WO-2013188856-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-12-19 — — WO disclosed
US-8026241-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2011-09-27 — — US disclosed
US-7582761-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-09-01 — — US disclosed
US-20090143575-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS BALAN CHENERA 2009-06-04 — — US disclosed
EP-1551811-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS Amgen Inc. (US) 2005-07-13 — — EP disclosed
US-20040152690-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-05 — — US disclosed
WO-2004035549-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS AMGEN INC. (US) 2004-04-29 — — WO disclosed
EP-1294700-A2 BENZHYDRYL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-26 — — EP disclosed
WO-2002000631-A2 BENZHYDRYL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338142-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, ZAP70, BTK PARP1 2611/4885PDK1 1730/4885PDK2 2745/4885
US-12319679-B2 Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors MAN2A1, MAN2B2, MGAT3 PARP1 3527/4885PDK1 1670/4885PDK2 1099/4885
US-20090143575-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV3, TRPV2 PARP1 3558/4885PDK1 3700/4885PDK2 3586/4885
US-12286434-B2 Pan-tropic entry inhibitors CXCR4, CCR5, CXCL12 PARP1 630/4885PDK1 544/4885PDK2 1130/4885
US-20040152690-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV3, TRPV2 PARP1 3543/4885PDK1 4051/4885PDK2 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.